| |
Stay ahead in AAV gene therapy—uncover vital strategies for immunogenicity assessment and companion diagnostics (CDx) approval.
Discover Key Strategies Now. +(002)+140w+(1).png)
|
|
Today’s Big NewsFeb 20, 2025 |
|
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome these challenges using AI cloud infrastructure and advanced machine learning tools. |
|
| By Gabrielle Masson CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendscho, Ph.D., confirmed with Fierce Biotech. |
|
|
|
By James Waldron Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to develop small-molecule medicines against undisclosed targets |
By Darren Incorvaia After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track Capital is publicly launching a proxy fight in a bid to steer the company in a new direction. |
Sponsored by Grifols Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor symptoms that significantly affects patients and their loved ones. |
By James Waldron Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs concerned about the upheaval and uncertainty surrounding federal grants. |
By Nick Paul Taylor UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette-Guérin therapy. |
By Gabrielle Masson While the FDA’s diversity guidance for clinical trials has been temporarily restored, the page it's housed on now carries a message from the Trump administration claiming that the guidance “does not reflect biological reality.” |
By Gabrielle Masson BioMed X Institute is teaming up with the Barbados government in an effort to accelerate cardiometabolic treatments for people of African descent. |
By Darren Incorvaia Clinical trial organization Flourish Research has made a deal with Diablo Clinical Research, acquiring the California-based facility and its expertise in endocrinology, cardiovascular and metabolic studies. |
By James Waldron AstraZeneca is paying $160 million for FibroGen’s Chinese business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat. |
By Fraiser Kansteiner Ahead of a meeting with President Donald Trump, trade group the Pharmaceutical Research and Manufacturers of America is welcoming its new board chair and drafting plans for government-industry collaboration in the coming months. |
By Darren Incorvaia Charles River Laboratories is continuing to downsize certain parts of its organization, reducing the workforce at its Memphis, Tennessee, cell and gene therapy facility, a spokesperson confirmed to Fierce Biotech. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
